Evidence map›Paper›PMID 35011684›Full record

ReviewCells2021

GILZ as a Regulator of Cell Fate and Inflammation.

Stefano Bruscoli, Carlo Riccardi, Simona Ronchetti

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Research progress on blood therapy for anti-aging.Journal of advanced research · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Role of histamine HInflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Stefano BruscoliDepartment of Medicine and Surgery, Section of Pharmacology, University of Perugia, 06132 Perugia, Italy.ORCID 0000-0003-0313-1615
Carlo RiccardiDepartment of Medicine and Surgery, Section of Pharmacology, University of Perugia, 06132 Perugia, Italy.ORCID 0000-0001-9257-3997
Simona RonchettiDepartment of Medicine and Surgery, Section of Pharmacology, University of Perugia, 06132 Perugia, Italy.ORCID 0000-0002-5639-4243
University of Perugia · IT

Funding

Italian Ministry of Education, University and Research PRIN-2017XZMBYX and PRIN 2017B9NCSX
6 · The paper itself

Abstract

One of the human body's initial responses to stress is the adrenal response, involving the release of mediators that include adrenaline and glucocorticoids (GC). GC are involved in controlling the inflammatory and immune response mechanisms. Of these, the molecular mechanisms that contribute to anti-inflammatory effects warrant more investigation. Previously, we found that GC induced GILZ (glucocorticoid-induced leucine zipper) quickly and widely in thymocytes, T lymphocytes, and other leukocytes. GILZ regulates the activation of cells and is an essential mediator of endogenous GC and the majority of GC anti-inflammatory effects. Further research in this regard could lead to the development of an anti-inflammatory treatment that yields the therapeutic outcomes of GC but without their characteristic adverse effects. Here, we examine the mechanisms of GILZ in the context of GC. Specifically, we review its role in the proliferation and differentiation of cells and in apoptosis. We also examine its involvement in immune cells (macrophages, neutrophils, dendritic cells, T and B lymphocytes), and in non-immune cells, including cancer cells. In conclusion, GILZ is an anti-inflammatory molecule that could mediate the immunomodulatory activities of GC, with less adverse effects, and could be a target molecule for designing new therapies to treat inflammatory diseases.

Indexed as

AnimalsCell DifferentiationGlucocorticoidsHumansInflammationMiceSignal TransductionTranscription FactorsDsip1 protein, mouseGlucocorticoidsTranscription FactorsGILZglucocorticoidimmune systeminflammation

Identifiers

PMID35011684
PMCPMC8750894
OpenAlexW4205579668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.